
Valdis Pirags

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4143774/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, The, 2005, 366, 1279-1289.	13.7	3,840
2	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, The, 2019, 394, 121-130.	13.7	1,625
3	Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine, 2012, 367, 319-328.	27.0	1,426
4	n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. New England Journal of Medicine, 2012, 367, 309-318.	27.0	810
5	Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke. Stroke, 2007, 38, 865-873.	2.0	459
6	Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nature Medicine, 2012, 18, 926-933.	30.7	414
7	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet, The, 2019, 394, 131-138.	13.7	394
8	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nature Genetics, 2016, 48, 1055-1059.	21.4	165
9	Design and baseline characteristics of participants in the <scp>R</scp> esearching cardiovascular <scp>E</scp> vents with a <scp>W</scp> eekly <scp>IN</scp> cretin in <scp>D</scp> iabetes (<scp>REWIND</scp>) trial on the cardiovascular effects of dulaglutide. Diabetes, Obesity and Metabolism, 2018, 20, 42-49.	4.4	160
10	Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. Journal of the American Society of Nephrology: JASN, 2019, 30, 2000-2016.	6.1	135
11	Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia, 2001, 44, 188-195.	6.3	130
12	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurology, The, 2020, 19, 582-590.	10.2	123
13	Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacogenetics and Genomics, 2012, 22, 659-666.	1.5	105
14	Association of metformin administration with gut microbiome dysbiosis in healthy volunteers. PLoS ONE, 2018, 13, e0204317.	2.5	96
15	Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 2010, 121, 1176-1187.	1.6	95
16	<i>Fatty liver index</i> and <i>hepatic steatosis index for prediction of</i> nonâ€alcoholic fatty liver disease in type 1 diabetes. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 270-276.	2.8	88
17	Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia, 2010, 53, 1258-1269.	6.3	85
18	Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes, Obesity and Metabolism, 2012, 14, 852-858.	4.4	83

#	Article	IF	CITATIONS
19	Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Metaâ€Analysis. Clinical Pharmacology and Therapeutics, 2017, 101, 763-772.	4.7	79
20	The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care, 2014, 37, 1360-1366.	8.6	76
21	Impact of peripheral arterial disease in patients with diabetes—Results from PROactive (PROactive 11). Atherosclerosis, 2009, 202, 272-281.	0.8	75
22	The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy. Diabetes Care, 2013, 36, 565-568.	8.6	69
23	The Dlabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2005, 6, 25-32.	1.7	59
24	Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). Diabetes Care, 2016, 39, 709-716.	8.6	55
25	Standardized Map of Iodine Status in Europe. Thyroid, 2020, 30, 1346-1354.	4.5	55
26	The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy. Diabetes Care, 2014, 37, 1924-1930.	8.6	54
27	Pioglitazone Use in Combination with Insulin in the Prospective Pioglitazone Clinical Trial in Macrovascular Events Study (PROactive19). Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2163-2171.	3.6	53
28	High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry. European Journal of Endocrinology, 2019, 181, 461-472.	3.7	53
29	The Dlabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 255-261.	1.7	50
30	Association of reduced glyoxalase 1 activity and painful peripheral diabetic neuropathy in type 1 and 2 diabetes mellitus patients. Journal of Diabetes and Its Complications, 2013, 27, 262-267.	2.3	43
31	Prevalence of Helicobacter pylori infection and atrophic gastritis in Latvia. European Journal of Gastroenterology and Hepatology, 2012, 24, 1410-1417.	1.6	41
32	Identification of glyoxalase 1 polymorphisms associated with enzyme activity. Gene, 2013, 515, 140-143.	2.2	37
33	Two HLA DRB 1 alleles confer independent genetic susceptibility to Graves disease: Relevance of cross-population studies. American Journal of Medical Genetics Part A, 2001, 102, 188-191.	2.4	35
34	Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal. Diabetes Care, 2011, 34, 1265-1269.	8.6	30
35	Ensuring Effective Prevention of Iodine Deficiency Disorders. Thyroid, 2016, 26, 189-196.	4.5	30
36	Baseline gut microbiome composition predicts metformin therapy short-term efficacy in newly diagnosed type 2 diabetes patients. PLoS ONE, 2020, 15, e0241338.	2.5	30

#	Article	IF	CITATIONS
37	Single nucleotide polymorphisms in the intergenic region between metformin transporter OCT2 and OCT3 coding genes are associated with short-term response to metformin monotherapy in type 2 diabetes mellitus patients. European Journal of Endocrinology, 2016, 175, 531-540.	3.7	24
38	Polymorphisms in FTO and near TMEM18 associate with type 2 diabetes and predispose to younger age at diagnosis of diabetes. Gene, 2013, 527, 462-468.	2.2	23
39	Association of Microsatellite Polymorphisms of the Human 14q13.2 Region with Type 2 Diabetes Mellitus in Latvian and Finnish Populations. Annals of Human Genetics, 2007, 71, 772-776.	0.8	22
40	Significantly altered peripheral blood cell DNA methylation profile as a result of immediate effect of metformin use in healthy individuals. Clinical Epigenetics, 2018, 10, 156.	4.1	22
41	Relation of inflammatory chemokines to insulin resistance and hypoadiponectinemia in coronary artery disease patients. European Journal of Internal Medicine, 2009, 20, 712-717.	2.2	20
42	lodine deficiency during pregnancy: a national cross-sectional survey in Latvia. Public Health Nutrition, 2015, 18, 2990-2997.	2.2	20
43	Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly. European Journal of Endocrinology, 2011, 165, 517-525.	3.7	19
44	A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. Diabetes and Vascular Disease Research, 2013, 10, 277-286.	2.0	19
45	Survey of autoantibody responses against tumor-associated antigens in thyroid cancer. Cancer Biomarkers, 2014, 14, 361-369.	1.7	19
46	Metformin strongly affects transcriptome of peripheral blood cells in healthy individuals. PLoS ONE, 2019, 14, e0224835.	2.5	19
47	Seasonal Iodine Deficiency in Latvian School Children. Thyroid, 2012, 22, 1088-1089.	4.5	17
48	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. European Heart Journal, 2021, 42, 2565-2573.	2.2	17
49	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 484-490.	11.4	17
50	Microsatellite genotyping of Chromosome 14q13.2-14q13 in the vicinity of proteasomal gene PSMA6 and association with Graves? disease in the Latvian population. Immunogenetics, 2004, 56, 238-43.	2.4	16
51	Association between a rare SNP in the second intron of human Agouti related protein gene and increased BMI. BMC Medical Genetics, 2009, 10, 63.	2.1	16
52	Whole-blood transcriptome profiling reveals signatures of metformin and its therapeutic response. PLoS ONE, 2020, 15, e0237400.	2.5	16
53	Single nucleotide polymorphisms of the purinergic 1 receptor are not associated with myocardial infarction in a Latvian population. Molecular Biology Reports, 2012, 39, 1917-1925.	2.3	15
54	The role of common and rare MC4R variants and FTO polymorphisms in extreme form of obesity. Molecular Biology Reports, 2014, 41, 1491-1500.	2.3	14

#	Article	IF	CITATIONS
55	A cross-sectional survey of urinary iodine status in Latvia. Medicina (Lithuania), 2014, 50, 124-129.	2.0	14
56	Functional Characteristics of Multipotent Mesenchymal Stromal Cells from Pituitary Adenomas. Stem Cells International, 2016, 2016, 1-11.	2.5	14
57	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. Cardiovascular Diabetology, 2020, 19, 199.	6.8	14
58	Nitric Oxide Production and Arachidonic Acid Metabolism in Platelet Membranes of Coronary Heart Disease Patients with and without Diabetes. Medical Principles and Practice, 2003, 12, 10-16.	2.4	13
59	Selenium status in patients with autoimmune and non-autoimmune thyroid diseases from four European countries. Expert Review of Endocrinology and Metabolism, 2014, 9, 685-692.	2.4	12
60	Prevalence estimation of celiac disease in the general adult population of Latvia using serology and HLA genotyping. United European Gastroenterology Journal, 2015, 3, 190-199.	3.8	11
61	Nitric oxide metabolism is impaired by type 1 diabetes and diabetic nephropathy. Biomedical Reports, 2020, 12, 251-258.	2.0	11
62	Acute and multiple-dose studies to determine the safety, tolerability, and pharmacokinetic profile of advantame in healthy volunteers. Food and Chemical Toxicology, 2011, 49, S77-S83.	3.6	10
63	A Nonsynonymous Variant I248L of the Adenosine A3 Receptor Is Associated with Coronary Heart Disease in a Latvian Population. DNA and Cell Biology, 2011, 30, 907-911.	1.9	10
64	Polymorphisms in MEN1 and DRD2 genes are associated with the occurrence and characteristics of pituitary adenomas. European Journal of Endocrinology, 2016, 175, 145-153.	3.7	10
65	Association between symptoms of depression, diabetes complications and vascular risk factors in four European cohorts of individuals with type 1 diabetes – InterDiane Consortium. Diabetes Research and Clinical Practice, 2020, 170, 108495.	2.8	10
66	Pepsinogen Test for the Evaluation of Precancerous Changes in Gastric Mucosa: a Population-Based Study. Journal of Gastrointestinal and Liver Diseases, 2019, 27, 11-17.	0.9	10
67	Trefoil factor 3 is required for differentiation of thyroid follicular cells and acts as aÂcontext-dependent tumor suppressor. Neoplasma, 2015, 62, 914-924.	1.6	9
68	Antibacterial and Anti-Inflammatory Potential of Polyherbal Formulation Used in Chronic Wound Healing. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-13.	1.2	9
69	SNPs of the PSMA6 gene: Investigation of possible association with myocardial infarction and type 2 diabetes mellitus. Russian Journal of Genetics, 2007, 43, 444-450.	0.6	7
70	Low risk of severe hypoglycaemia in patients with type 2 diabetes mellitus starting insulin therapy with premixed insulin analogues BID in outpatient settings. International Journal of Clinical Practice, 2012, 66, 1033-1041.	1.7	7
71	The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipidâ€lowering treatment strategies in diabetic subjects with and without metabolic syndrome. Diabetes, Obesity and Metabolism, 2013, 15, 513-522.	4.4	7
72	Angiopoietin 2 and Neuropeptide Y are Associated with Diabetic Kidney Disease in Type 1 Diabetes Mellitus. Experimental and Clinical Endocrinology and Diabetes, 2020, 128, 654-662.	1.2	7

#	Article	IF	CITATIONS
73	Validity of multiplex biomarker model of 6 genes for the differential diagnosis of thyroid nodules. Thyroid Research, 2011, 4, 11.	1.5	6
74	Stronger Association of Common Variants in TCF7L2 Gene with Nonobese Type 2 Diabetes in the Latvian Population. Experimental and Clinical Endocrinology and Diabetes, 2012, 120, 466-468.	1.2	6
75	Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects. Lipids in Health and Disease, 2013, 12, 103.	3.0	6
76	Evaluation of the Possibility to Detect Circulating Tumor DNA From Pituitary Adenoma. Frontiers in Endocrinology, 2019, 10, 615.	3.5	5
77	Impact of interval walking training managed through smart mobile devices on albuminuria and leptin/adiponectin ratio in patients with type 2 diabetes. Physiological Reports, 2020, 8, e14506.	1.7	5
78	Pituispheres Contain Genetic Variants Characteristic to Pituitary Adenoma Tumor Tissue. Frontiers in Endocrinology, 2020, 11, 313.	3.5	5
79	Medication for Acromegaly Reduces Expression of MUC16, MACC1 and GRHL2 in Pituitary Neuroendocrine Tumour Tissue. Frontiers in Oncology, 2020, 10, 593760.	2.8	4
80	Achievement of treatment targets predicts progression of vascular complications in type 1 diabetes. Journal of Diabetes and Its Complications, 2021, 35, 108072.	2.3	4
81	Hypercalcemia and CYP24A1 Gene Mutation Diagnosed in the 2nd Trimester of a Twin Pregnancy: A Case Report. American Journal of Case Reports, 2021, 22, e931116.	0.8	3
82	Interleukin-6 gene promoter –174G/C polymorphism and insulin resistance: a pilot study. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1145-8.	2.3	2
83	Analysis of Polymorphisms at the Adiponectin Gene Locus in Association with Type 2 Diabetes, Body Mass Index and Cardiovascular Traits in Latvian Population. Proceedings of the Latvian Academy of Sciences, 2009, 63, 174-179.	0.1	2
84	Case report: recurrent pituitary adenoma has increased load of somatic variants. BMC Endocrine Disorders, 2020, 20, 17.	2.2	2
85	Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3448-e3454.	3.6	2
86	Glucose Metabolism Disorders and Risk Factors of Type 2 Diabetes in 45-74-Years-old Population in Rīga, Latvia. Proceedings of the Latvian Academy of Sciences, 2009, 63, 141-146.	0.1	1
87	lodine Deficiency in Latvia: Current Status and Need for National Recommendations. Proceedings of the Latvian Academy of Sciences, 2017, 71, 401-407.	0.1	1
88	Bioinformatic Analysis of Evolutional Conservatism and Functional Significance of Microsatellite Alleles of Human 14Q13.2 Region Associated with Type 2 Diabetes Mellitus. Proceedings of the Latvian Academy of Sciences, 2008, 62, 91-102.	0.1	1
89	HAPLOGENDIS INITIATIVE - SICA. Acta Endocrinologica, 2009, 5, 143-148.	0.3	1
90	Consumption of Thyroid Medications as an Indicator of Increase of Thyroid Morbidity in Latvia from 2011 to 2014. Proceedings of the Latvian Academy of Sciences, 2019, 73, 407-410.	0.1	1

#	Article	IF	CITATIONS
91	Register-based information on thyroid diseases in Europe: lessons and results from the EUthyroid collaboration. Endocrine Connections, 2022, , .	1.9	1
92	Relation of Endothelial Dysfunction and Adipokines Levels to Insulin Resistance in Metabolic Syndrome Patients. Proceedings of the Latvian Academy of Sciences, 2009, 63, 222-227.	0.1	0
93	Report on Bariatric Surgery in Latvia. Obesity Surgery, 2021, 31, 2311-2313.	2.1	Ο